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INTRODUCTION
Mucolipidosis was first described by Leroy and Demars (1)
in 1967 as a new disorder that clinically resembled Hurler
syndrome but lacked mucopolysacchariduria. Another dis-
tinguishing feature of mucolipidois is the presence of large,
phase-dense inclusions in fibroblasts. Because these cells are
called inclusion cells (I-cells), the disorder came to be called
I-cell disease (mucolipidosis II, or ML-II). Similar inclusions
are seen in pseudo-Hurler polydystrophy (mucolipidosis III,
or ML-III), which is clinically milder than I-cell disease and
is presented later (2). ML-II and III are biochemically related
genetic diseases that are rare and recessively inherited in auto-
somes. One of the most striking biochemical features of these
disorders is the finding of markedly elevated levels of many
lysosomal enzymes in serum (2, 3). Cultured fibroblasts from
these patients show lower intracellular activities of the same
lysosomal enzymes (2, 4-6) and contain the characteristic inclu-
sion bodies. In both diseases, lysosomal enzyme transport is
abnormal in cells of mesenchymal origin. In normal cells, the
targeting of lysosomal enzymes to lysosomes is mediated by
receptors that bind mannose 6-phosphate recognition mark-
ers to the enzymes (7). The recognition marker is synthesized
in a two-step reaction in the Golgi complex, and is the enzyme
that catalyzes the first step in the process. This enzyme was
identified as N-acetylglucosamine-1-phosphotransferase, and
found to be defective in ML-II and ML-III (8, 9). As a conse-
quence of a defective recognition marker, newly synthesized
lysosomal enzymes are not targeted to lysosomes, but are sec-
reted into the extracellular space.
Ahn and Chung (10) reported upon a sibling of ML-III with
carpal tunnel syndrome, but the patients were not Korean. To
the best of our knowledge, this is the first report on a Korean
patient with ML-III. Biochemical studies were performed
upon the cultured fibroblast cells from this patient.
MATERIALS AND METHODS
Patient
A 1.5-yr-old girl first was taken into our out-patient clin-
ic for the evaluation of motor developmental delay and spine
deformity. She was delivered through normal, full-term, and
spontaneous process with 2.3 kg of the weight at birth. Chro-
mosomal study was normal. Characteristics of facial appear-
ance included frontal bossing, exophthalmos, hypertelorism,
and depressed midface. Simple radiographs revealed thora-
columbar kyphosis and acetabular dysplasia, but no epiphy-
seal dysplasia was noted. At age of 3.5 yr, she was measured
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Biochemical Characteristics of a Korean Patient with Mucolipidosis III
(Pseudo-Hurler Polydystrophy)
We performed a biochemical study on the patient with mucolipidosis III (ML-III, pseu-
do-Hurler polydystrophy) in Korea. Confluent fibroblasts from the patient and from
normal controls were cultured for 4, 12, 24, 48, and 72 hr, respectively. Lysosomal
enzyme activities in culture media after different incubation times and in plasma, leuko-
cytes, and fibroblasts were determined. Most of the leukocyte lysosomal enzymes
were within normal limits or slightly lowered; however, plasma lysosomal enzyme
activities such as those of hexosaminidase and arylsulfatase A were markedly in-
creased. Numerous phase-dense inclusions were present in the cytoplasm of cul-
tured fibroblasts. Lysosomal enzyme activities of fibroblasts were markedly decreased
except for  -glucosidase. The rates of increase of the lysosomal enzyme activities
with incubation time were greater in the culture medium of the patient than in normal
control, whereas no difference in the  -glucosidase activity of the culture media of
the patient and the control was found. This study describes the first case of ML-III
in Korea, with its typical biochemical characteristics, i.e., a problem with targeting
and transporting of lysosomal enzymes which results in a marked increase in plas-
ma lysosomal enzyme activities and a high ratio of extracellular to intracellular lyso-
somal enzyme activities in cultured fibroblasts.
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at 87 cm in height (<1%). She had 30 degree flexion contrac-
ture of both hip and knee joints (Fig. 1). She could walk alone
only after she became 4 yr-old. At that time, hepatospleno-
megaly and frequent constipation were noted. Cardiac echocar-
diography showed a thick left ventricular wall. At age of 5 yr,
papilledema due to increased intracranial pressure and cran-
iosynostosis was noted and confirmed. Conductive loss of hear-
ing due to chronic otitis media, mild mental retardation, and
language developmental delay were found. Urinary mucopoly-
saccharide spot test was negative. Under the impression of
mucolipidosis, laboratory tests including enzyme assay from
circulating leukocyte, plasma, and cultured dermal fibroblast
were performed. No specific therapeutic measurement was
carried out.
Chemicals
4-Methylumbelliferone, 4-methylumbelliferyl (MU)- -D-
glucuronide, 4-MU- -D-glucopyranoside, 4-MU- -D-ga-
lactopyranoside, 4-MU- -D-galactopyranoside, 4-MU-2-ace-
tamido-2-deoxy- -D-glucopyranoside, 4-MU-2-acetamido-
2-deoxy- -D-glucopyranoside, and p-nitrocatechol sulfate were
purchased from the Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Samples
Leukocytes and plasma were prepared from heparinized
peripheral blood specimens. Skin fibroblasts were obtained
from skin punch biopsies of the patient and from normal con-
trols. Cultured skin fibroblasts were propagated and main-
tained in Medium 199 supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100  g/mL streptomycin.
Confluent cells were trypsinized for lysosomal enzyme assay.
Lysosomal enzyme activity changes in culture medi-
um with time
After seeding the equal number of cells into five culture
flasks, the old medium was replaced with the fresh medium.
Each flask was cultured for 4, 12, 24, 48, and 72 hr, respec-
tively, and lysosomal enzyme activities in culture medium
were determined.
Lysosomal enzyme assays
Lysosomal enzyme activities including  -N-acetylglu-
cosaminidase, hexosaminidase,  -galactosidase,  -galactosi-
dase,  -glucosidase and  -glucuronidase in samples of plas-
ma, leukocytes, cultured fibroblasts and culture media were
determined by using appropriate methylumbelliferyl fluoro-
genic substrates and by commonly used methods (11). The
fluorescence was compared with a standard solution of 4-
methylumbelliferone using a Jasco FP-55A spectrofluorom-
eter (Easton, MD, U.S.A.) with the excitation wavelength at
360 nm and the emission wavelength at 448 nm. Arylsulfa-
tase A and B were also measured, using p-nitrocatechol sul-
fate as substrate (11). The normal ranges of lysosomal enzymes
were adopted from those of the laboratory manuals (11) and
were verified by measuring several control samples in the pre-
sent study. Protein was measured by using the method of Lowry
et al. (12). Enzyme activities of leukocytes and cultured fibro-
blasts were expressed as nmoles of substrate cleaved per mg
of cell protein per hour at 37℃. Enzyme activities in plasma
and in culture medium were expressed as nmoles of substrate
cleaved per mL per hour at 37℃.
*Enzyme activity is expressed as nanomoles of substrate liberated per
mg of cell per hour. 
� Enzyme activity is expressed as nanomoles of
substrate liberated per ml of plasma per hour. nd: not determined.
Lysosomal enzyme activities (normal range)
Leukocytes* Plasma
� Cultured
Fibroblasts*
-N-acetylglu- 1.2 (0.7-1.7) nd 3.9 (11-21)
cosaminidase
-galactosidase 52 (80-140) nd 26 (80-140)
Arylsulfatase B 354 (115-226) nd 67 (530-950)
-glucuronidase 202 (350-500) nd 47 (75-155)
Hexosaminidase nd 11,687 (800-1,600) 911 (3,000-5,000)
Arylsulfatase A nd 62.2 (1.3-2.4) 16 (190-405)
-glucosidase nd nd 329 (320-550)
-galactosidase nd nd 11 (40-110)
Table 1. Lysosomal enzyme activities in leukocyte, plasma and
cultured fibroblasts from the patient with pseudo-Hurler poly-
dystrophy
Fig. 1. A patient with pseudo-Hurler polydystrophy at the age of
3.5 yr; note the coarse face and 30 degree flexion contracture of
both hip and knee joints.724 J. Song, D.S. Lee, H.I. Cho, et al.
RESULTS
Leukocyte and plasma lysosomal enzyme activities are shown
in Table 1. Most of the leukocyte lysosomal enzyme levels were
normal or slightly reduced; however, plasma lysosomal enzy-
mes, such as hexosaminidase and arylsulfatase A, were marked-
ly elevated. A complete assay for all lysosomal enzymes was
not performed because of the loss of the patient to conduct a
follow-up.
In the cytoplasm of cultured fibroblasts, numerous phase-
dense inclusions was observed, although not prominent (Fig.
2). Lysosomal enzyme levels in cultured fibroblasts were
markedly reduced except for  -glucosidase (Table 1).
The changes in the lysosomal enzyme activities in culture
medium with incubation time are shown in Fig. 3. The rates
of increase of lysosomal enzyme activities in the culture medi-
um of the patient were greater than in the culture medium of
normal control, whereas no difference in  -glucosidase activ-
ity was found in the culture media of the patient and of the
control.
DISCUSSION
ML-II and III reflect multiple deficiencies of many lysoso-
mal hydrolases, and require posttranslational processing to
form a recognition site that permits their cellular uptake. The
fundamental defect is found in N-acetylglucosaminyl phos-
photransferase, which results in abnormal lysosomal enzyme
transport in cells (8, 9, 13). In such cells, newly synthesized
lysosomal enzymes are secreted into the extracellular medium
instead of being targeted correctly to lysosomes. Patients with
ML-II have a complete deficiency of this enzyme, while patients
with ML-III have varying amounts of residual enzymic activi-
ties. Both ML-II and III show many of clinical and radiograph-
ic features of the classic mucopolysaccharidoses: such as dyso-
stosis multiplex and coarse facial features. However, unlike pa-
tients with mucopolysaccharidoses, patients with ML have
no mucopolysacchariduria. ML-II shows as a severe progres-
sive psychomotor retardation, and death usually occurs in the
first decade. ML-III is milder and presents later, and survival
into adulthood is possible (2). In the case described, until bio-
chemical confirmatory diagnosis for ML-III had been obtained,
the patient was clinically considered as mucopolysaccharido-
sis with unusual laboratory findings, such as no mucopolysac-
chariduria and normal or slightly reduced leukocyte enzyme
activities for mucopolysacchridoses. Even though the assay
for N-acetylglucosaminyl phosphotransferase enzyme activity
was not performed in this patient, the patient was diagnosed
as ML-III because she had relatively mild clinical manifesta-
tions and typical biochemical findings.
The biochemical diagnosis of ML-II and ML-III can be made
by measuring the activities of lysosomal enzymes in serum
or in cultured fibroblasts. In general, a ten- to twenty-fold
increase in serum lysosomal enzymes is diagnostic of these
disorders (2, 3). If cultured fibroblasts are available, the char-
acteristic pattern of lysosomal enzyme deficiencies may be
used, as well as the ratio of extracellular to intracellular enzyme
activities for diagnosis (5, 6). In this presentation, the patient
showed a marked increase in plasma lysosomal enzymes, such
as hexosaminidase and arylsulfatase A. Lysosomal enzyme lev-
els in cultured fibroblasts were markedly decreased, and also
Fig. 2. Phase contrast microscopy of cultured fibroblasts; (A) from a patient with pseudo-Hurler polydystrophy and (B) from a control.
Dense inclusions are present throughout the cytoplasm of a patient.
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those in cultured fibroblast media were markedly reduced.
This was caused by the secretion of newly synthesized intra-
cellular lysosomal enzyme into extracellular media instead of
being targeted correctly to lysosomes. Moreover, the fibro-
blasts were deficient in a large number of lysosomal enzymes
due to the hypersecretion of these proteins.
To elucidate this secretory phenomenon into the extracel-
lular media more precisely, we investigated the time course
of enzymatic activities in the fibroblast culture medium from
a patient with pseudo-Hurler polydystrophy and from a con-
trol (Fig. 3). After seeding equal numbers of cells into five
culture flasks, the old medium was replaced with fresh medi-
um. Each flask was cultured for 4, 12, 24, 48, and 72 hr, re-
spectively, and lysosomal enzyme activities in culture medi-
um were determined. The rates of increase of the lysosomal
enzyme activities with incubation time were greater in the
media of pseudo-Hurler polydystrophy (ML-III) fibroblast
culture than in normal fibroblast culture; which means that
the normal transport of lysosomal enzymes to lysosomes is
impaired and that extracellular secretion is increased as a con-
sequence.
Interestingly, no difference was found in  -glucosidase activi-
ty of the culture media of the patient and of the control. Fur-
thermore, the activity of  -glucosidase in the fibroblasts of the
patient was normal. This enzyme is known to be targeted to
lysosomes by a phosphorylation-independent mechanism (14).
However, the exact targeting mechanism of  -glucosidase
remained to be clarified. Acid phosphatase is another enzyme
that does not use the mannose 6-phosphate targeting path-
way. Acid phosphatase is made as a transmembrane protein,
Fig. 3. Time course changes of lysosomal enzyme activity in fibroblast culture medi-
um form a patient with pseudo-Hurler polydystrophy (■) and from a control (○). After
seeding equal numbers of cells into five culture flasks, the old medium was replaced
with fresh medium. Each flask was cultured 4, 12, 24, 48, and 72 hr, respectively, and
substrate liberated per mL of culture medium per hour.
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and its lysosomal targeting signal is contained in its cytoplas-
mic tail (15).
ML-III is genetically and clinically heterogenous (16-18).
It can be divided into three distinct complementation groups:
Complementation group A, the classic and the more frequent,
is characterized by decreased phosphotransferase when deter-
mined using artificial and natural substrates: Complemen-
tation group C is characterized by a deficient activity when
determined using natural substrate but normal activity using
artificial substrate; and Complementation group B is very rare
and its phosphotransferase properties are similar to those group
A. Recently, there was a report on mutation analysis in a group
C patient (19, 20). However, because the phosphotransferase
assay was not conducted in our patient, it is not possible to
place it in a complementation group. More studies on phos-
photransferase activity and mutation analysis are needed.
In conclusion, we report the first Korean case of ML-III,
pseudo-Hurler polydystrophy, with typical biochemical find-
ings that show the problem of lysosomal enzyme targeting
and transport, which results in a marked increase in plasma
lysosomal enzyme activity and an increased ratio of extracel-
lular to intracellular lysosomal enzyme activity in cultured
fibroblasts.
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